Anthracyclines as effective anticancer drugs (Q38090650)

28 August 2017

title

Anthracyclines as effective anticancer drugs (English)

1 reference

28 August 2017

Janos Nadas

1

1 reference

28 August 2017

Duxin Sun

series ordinal

2

1 reference

28 August 2017

language of work or name

English

0 references

publication date

1 November 2006

1 reference

Expert Opinion on Drug Discovery

28 August 2017

published in

1 reference

28 August 2017

volume

1

1 reference

28 August 2017

issue

6

1 reference

28 August 2017

page(s)

549-568

1 reference

Epirubicin. An updated review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in the management of breast cancer

28 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F17460441.1.6.549

Doxorubicin disaccharide analogue: apoptosis-related improvement of efficacy in vivo.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.1.6.549

Culprit and victim -- DNA topoisomerase II.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.1.6.549

Recent developments in the field of antitumour anthracyclines

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.1.6.549

Anthracyclines: selected new developments

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.1.6.549

A critical evaluation of the mechanisms of action proposed for the antitumor effects of the anthracycline antibiotics adriamycin and daunorubicin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.1.6.549

Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.1.6.549

Anthracycline analogs: the past, present, and future

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.1.6.549

Anthracycline cardiotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.1.6.549

DNA topoisomerases as targets for anticancer drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.1.6.549

DNA topoisomerases: structure, function, and mechanism

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.1.6.549

A model for the mechanism of human topoisomerase I

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.1.6.549

Structure and mechanism of DNA topoisomerase II

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.1.6.549

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.1.6.549

A protein-mediated mechanism for the DNA sequence-specific action of topoisomerase II poisons.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.1.6.549

Interaction model for anthracycline activity against DNA topoisomerase II.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.1.6.549

DNA topoisomerase poisons as antitumor drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.1.6.549

The mechanism of type IA topoisomerases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.1.6.549

A structural model for the ternary cleavable complex formed between human topoisomerase I, DNA, and camptothecin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.1.6.549

Human DNA topoisomerase I: relaxation, roles, and damage control

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.1.6.549

Catalytic topoisomerase II inhibitors in cancer therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.1.6.549

Discovery of a daunorubicin analogue that exhibits potent antitumor activity and overcomes P-gp-mediated drug resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.1.6.549

The power and potential of doxorubicin-DNA adducts

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.1.6.549

Cytotoxicity, cellular uptake and DNA damage by daunorubicin and its new analogues with modified daunosamine moiety

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.1.6.549

Cell death by mitotic catastrophe: a molecular definition

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.1.6.549

Computerized video time lapse study of cell cycle delay and arrest, mitotic catastrophe, apoptosis and clonogenic survival in irradiated 14-3-3sigma and CDKN1A (p21) knockout cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.1.6.549

Two distinct modes of cell death induced by doxorubicin: apoptosis and cell death through mitotic catastrophe accompanied by senescence-like phenotype

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.1.6.549

Transcriptional changes facilitate mitotic catastrophe in tumour cells that contain functional p53.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.1.6.549

A new bisintercalating anthracycline with picomolar DNA binding affinity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.1.6.549

WP744 is a novel anthracycline with enhanced activity against neuroblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.1.6.549

Multidrug resistance proteins: role of P-glycoprotein, MRP1, MRP2, and BCRP (ABCG2) in tissue defense

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.1.6.549

Structural biology. The xyz of ABC transporters

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.1.6.549

The ATP switch model for ABC transporters

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.1.6.549

P-glycoprotein as a drug target in the treatment of multidrug resistant cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.1.6.549

Cellular resistance to anthracyclines.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.1.6.549

The contribution of P-glycoprotein to pharmacokinetic drug-drug interactions

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.1.6.549

The topography of transmembrane segment six is altered during the catalytic cycle of P-glycoprotein.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.1.6.549

The structures of MsbA: Insight into ABC transporter-mediated multidrug efflux

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.1.6.549

RETRACTED: Structure of the ABC transporter MsbA in complex with ADP.vanadate and lipopolysaccharide

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.1.6.549

Structure of MsbA from Vibrio cholera: a multidrug resistance ABC transporter homolog in a closed conformation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.1.6.549

Photoaffinity labeling of P-glycoprotein

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.1.6.549

Transport of anthracyclines and mitoxantrone across membranes by a flip-flop mechanism

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.1.6.549

P-glycoprotein: from genomics to mechanism.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.1.6.549

Multidrug resistance mediated by the breast cancer resistance protein BCRP (ABCG2)

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.1.6.549

The human ATP-binding cassette transporter genes: from the bench to the bedside

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.1.6.549

Syntheses and biological activities of 3'-azido disaccharide analogues of daunorubicin against drug-resistant leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.1.6.549

Enzymatic and chemical footprinting of anthracycline antitumor antibiotics and related saccharide side chains

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.1.6.549

Syntheses and biological activities of rebeccamycin analogues with uncommon sugars

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.1.6.549

Binding affinity and site selectivity of daunomycin analogues

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.1.6.549

Structure by NMR of antitumor drugs aclacinomycin A and B complexed to d(CGTACG).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.1.6.549

Pharmacokinetics of pegylated liposomal Doxorubicin: review of animal and human studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.1.6.549

Effects of mixed polyethyleneglycol modification on fixed aqueous layer thickness and antitumor activity of doxorubicin containing liposome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.1.6.549

Characterization and cytotoxicity of mixed polyethyleneglycol modified liposomes containing doxorubicin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.1.6.549

Development of pH-sensitive liposomes that efficiently retain encapsulated doxorubicin (DXR) in blood

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.1.6.549

Role of pegylated liposomal doxorubicin in ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.1.6.549

Doxorubicin loaded pH-sensitive polymeric micelles for reversal of resistant MCF-7 tumor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.1.6.549

Phase I clinical trial of topotecan and pegylated liposomal doxorubicin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.1.6.549

Phase I dose escalation study of pegylated liposomal doxorubicin (Caelyx) in combination with topotecan in patients with advanced malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.1.6.549

A dose escalation study of pegylated liposomal Doxorubicin (caelyx) in combination with capecitabine (xeloda) in patients with refractory solid tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.1.6.549

The use of liposomal daunorubicin (DaunoXome) in acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.1.6.549

Ifosfamide/liposomal daunorubicin is a well tolerated and active first-line chemotherapy regimen in advanced soft tissue sarcoma: results of a phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.1.6.549

A phase II study on the safety and efficacy of 5-fluorouracil, epirubicin, cyclophosphamide (FEC) followed by paclitaxel in the adjuvant treatment of breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.1.6.549

Epirubicin, cyclophosphamide and weekly paclitaxel as neoadjuvant chemotherapy for stage II and III breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.1.6.549

Phase II trial of neoadjuvant chemotherapy with docetaxel followed by epirubicin in stage II/III breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.1.6.549

Multicenter phase II study of trastuzumab in combination with epirubicin and docetaxel as first-line treatment for HER2-overexpressing metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.1.6.549

Is epirubicin effective in first-line chemotherapy of metastatic breast cancer (MBC) after an epirubicin-containing adjuvant treatment? A single centre phase III trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.1.6.549

Estimates of the worldwide mortality from 25 cancers in 1990.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.1.6.549

Bi-weekly chemotherapy with cisplatin, epirubicin, folinic acid and 5-fluororacil continuous infusion plus g-csf in advanced gastric cancer: a multicentric phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.1.6.549

A phase II study of epirubicin, cisplatin and capecitabine combination chemotherapy in patients with metastatic or advanced gastric cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.1.6.549

Final results of a prospective trial of a PEFG (Cisplatin, Epirubicin, 5-Fluorouracil, Gemcitabine) regimen followed by radiotherapy after curative surgery for pancreatic adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.1.6.549

Intensive chemotherapy with idarubicin, cytarabine, etoposide, and G-CSF priming in patients with advanced myelodysplastic syndrome and high-risk acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.1.6.549

Multicentre phase III trial on fludarabine, cytarabine (Ara-C), and idarubicin versus idarubicin, Ara-C and etoposide for induction treatment of younger, newly diagnosed acute myeloid leukaemia patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.1.6.549

Idarubicin and standard-dose cytosine arabinoside in adults with recurrent and refractory acute lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.1.6.549

The crystal structure of the complex between a disaccharide anthracycline and the DNA hexamer d(CGATCG) reveals two different binding sites involving two DNA duplexes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.1.6.549

Role of the amino sugar in the DNA binding of disaccharide anthracyclines: crystal structure of the complex MAR70/d(CGATCG).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.1.6.549

A phase II study of sabarubicin (MEN-10755) as second line therapy in patients with locally advanced or metastatic platinum/taxane resistant ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.1.6.549

Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.1.6.549

Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.1.6.549

Antitumor activity of methoxymorpholinyl doxorubicin: potentiation by cytochrome P450 3A metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.1.6.549

Formation and antitumor activity of PNU-159682, a major metabolite of nemorubicin in human liver microsomes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.1.6.549

Structures of three classes of anticancer agents bound to the human topoisomerase I-DNA covalent complex

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.1.6.549

Structure of the topoisomerase II ATPase region and its mechanism of inhibition by the chemotherapeutic agent ICRF-187

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.1.6.549

Quaternary changes in topoisomerase II may direct orthogonal movement of two DNA strands

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.1.6.549

XK469, a selective topoisomerase IIbeta poison

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.1.6.549

A computational model for anthracycline binding to DNA: tuning groove-binding intercalators for specific sequences.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.1.6.549

Role of the sugar moiety in the pharmacological activity of anthracyclines: development of a novel series of disaccharide analogs.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.1.6.549

Novel anthracycline oligosaccharides: influence of chemical modifications of the carbohydrate moiety on biological activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.1.6.549

Probucol protects against adriamycin cardiomyopathy without interfering with its antitumor effect

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.1.6.549

Comparison of doxorubicin- and MEN 10755-induced long-term progressive cardiotoxicity in the rat

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.1.6.549

Chronic cardiotoxicity of anticancer anthracyclines in the rat: role of secondary metabolites and reduced toxicity by a novel anthracycline with impaired metabolite formation and reactivity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.1.6.549

Correlation of the acid-sensitivity of polyethylene glycol daunorubicin conjugates with their in vitro antiproliferative activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.1.6.549

21 January 2018

Identifiers

DOI

10.1517/17460441.1.6.549

1 reference

28 August 2017

1 reference